Dramatic Growth in Cancer Rates Predicted for Elderly, Minorities

Publication
Article
OncologyONCOLOGY Vol 23 No 6
Volume 23
Issue 6

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly (67% increase) and minority (100% increase) populations, according to research from The University of Texas M. D. Anderson Cancer Center.

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45%, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly (67% increase) and minority (100% increase) populations, according to research from The University of Texas M. D. Anderson Cancer Center. The study was based on statistics from the US Census Bureau and the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) registry.

Articles in this issue
Mate (Ilex paraguariensis)
Mate (Ilex paraguariensis)
Therapeutic Options in Relapsed or Refractory Diffuse Large B-cell Lymphoma: Part 1
Key Questions for Perioperative Chemotherapy in Resectable Lung Cancer
Adjuvant or Induction Cisplatin-Based Chemotherapy for Operable Lung Cancer
Adjuvant vs Neoadjuvant Chemotherapy in Resectable NSCLC: Is That the Real Question?
Pregnancy and Fertility With Breast Cancer: What Are the Options?
Breast Cancer in Women Under 40
Complexities of Adjuvant Endocrine Therapy in Young Premenopausal Women
Breast Cancer in Young Women: Clinical Decision-Making in the Face of Uncertainty
NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus
Dramatic Growth in Cancer Rates Predicted for Elderly, Minorities
Penn Study Examines Power of Exercise to Prevent Breast Cancer
The Pathway Ahead in Melanoma Trials
Treating Metastatic Melanoma: Further Considerations
Treatment of Metastatic Melanoma: An Overview
Treatment of Metastatic Melanoma: An Overview
Recent Videos
Related Content
Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.